Correction: Zealand Pharma major shareholder announcement: Polar Capital LLP, April 7 2022GlobeNewsWire • 04/07/22
Zealand Pharma major shareholder announcement: The Capital Group Companies, April 7 2022GlobeNewsWire • 04/07/22
Zealand Pharma to Participate in 21st Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/04/22
Zealand Pharma Appoints New Chief Executive Officer, Refocuses Strategy to Prioritize Research & Development and Streamlines OperationsGlobeNewsWire • 03/30/22
Correction: Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglutide and Dasiglucagon Programs Expected in 2022.GlobeNewsWire • 03/11/22
Zealand Pharma A/S (ZEAL) CEO Emmanuel Dulac on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/10/22
Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglutide and Dasiglucagon Programs Expected in 2022.GlobeNewsWire • 03/10/22
Zealand Pharma Hosts Conference Call on March 10 at 4 pm CET (10am ET) to Present Full Year Results for 2021GlobeNewsWire • 03/03/22
Zealand Pharma major shareholder announcement: The Capital Group Companies, 2022GlobeNewsWire • 02/25/22
Zealand Pharma Completes Enrollment in Phase 3 Trial of Dasiglucagon in Children with Congenital Hyperinsulinism (CHI)GlobeNewsWire • 02/15/22
Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel SyndromeGlobeNewsWire • 01/20/22
Zealand Pharma major shareholder announcement: The Capital Group Companies, January 2022GlobeNewsWire • 01/19/22
Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021GlobeNewsWire • 12/24/21
Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel SyndromeGlobeNewsWire • 12/16/21
Zealand Pharma Announces Seven-Year, $200 Million Financing Agreement with Oberland CapitalGlobeNewsWire • 12/14/21
Zealand Pharma increases its share capital as a consequence of exercise of employee warrantsGlobeNewsWire • 12/10/21
Zealand Pharma announces successful outcome of Phase 1b clinical trial with GLP1-GLP2 dual receptor agonist, dapiglutideGlobeNewsWire • 11/22/21
Zealand Pharma A/S (ZEAL) CEO Emmanuel Dulac on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/11/21
Zealand Pharma Presents Financial Results for the First Nine Months of 2021; Provides Updates on Commercial Launch and Timing for Congenital Hyperinsulinism and Short Bowel Syndrome Phase Three Clinical StudiesGlobeNewsWire • 11/11/21